In 2021 We Were Named the Leader in DCT. In 2022, We Will Expand Patient Access by 100%. Learn How

In 2021, Medable grew by 400%, helping further the rise of decentralized trials and patient-centric care. 

The end result was: 

  • Releasing the first-ever financial modeling along with Tufts, showing the positive ROI associated with DCTs
  • Being named the leading DCT provider by Everest
  • More than 70,000 patients screened in a year, across 126 trial protocols, and 
  • Convenient care with 2.1 million hours of televisits across 82 clinical trial sites 

Looking to learn more and see what’s coming in 2022? Grab a free copy of your report here. 

No items found.
Download now

Save the Date!